Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Torrent Pharma has emerged as a top sectoral pick for brokerages, driven by healthy growth in India revenues and improved gross margins, leading to a 44 per cent stock return over the past year.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
The World Health Organization has requested information from the Indian government regarding the alleged supply of spurious oxytocin injections linked to the deaths of five women in Kota hospitals. This comes after regulatory action, including the cancellation of manufacturing licenses for Jackson Laboratories units, following joint inspections by drug control bodies. The government is investigating the matter, emphasising a zero-tolerance approach to quality violations.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Indian benchmark indices, Sensex and Nifty, experienced declines in early trade due to a surge in crude oil prices and significant selling pressure on bank stocks, impacting overall investor sentiment. Track Sensex, Nifty on July 22.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
US President Donald Trump announced steep tariffs on imported generic medicines, effective from August 2028, with the aim of boosting domestic pharmaceutical production. This policy, which includes a phased increase in tariffs up to 200 per cent, could significantly impact India, a major global supplier of generic drugs to the US market.
India's outward foreign direct investment (FDI) plummeted by 47.9 per cent year-on-year to $3 billion in June 2026, according to the Reserve Bank of India (RBI), with declines across equity, debt, and guarantee commitments.
Indian benchmark indices Sensex and Nifty rebounded in early trade after three days of decline, driven by a rally in Sun Pharma following its USD 11.75 billion acquisition of US-based Organon & Co, alongside a positive trend in global equity markets.
Homegrown pharma major Cipla Ltd reported a 39 per cent decline in consolidated net profit to Rs 785.55 crore in the first quarter ended June 2026, primarily due to a dip in sales in the North American market and higher expenses.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, with the Sensex falling over 500 points and the Nifty over 150 points, as Brent crude oil prices surged past USD 100 per barrel due to escalating geopolitical tensions in the West Asia. track sensex, Nifty on July 24.
Indian benchmark indices Sensex and Nifty experienced a downturn in early trade, primarily influenced by a dip in HDFC Bank shares, persistent outflows from foreign funds, and escalating geopolitical tensions between the US and Iran. Track Sensex, Nifty performance.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, driven by renewed tensions between the US and Iran and a subsequent spike in global crude oil prices, creating uncertainty in the market. Track Sensex, Nifty on July 8.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
Indian benchmark indices Sensex and Nifty rallied in early trade, primarily driven by strong buying in IT stocks after Tech Mahindra reported a significant 28.4 per cent rise in its consolidated net profit for the June quarter.
Indian benchmark indices Sensex and Nifty rebounded in early trade on Thursday, recovering from a sharp fall in the previous session, driven by foreign fund inflows and buying in key blue-chip stocks. Track Sensex, Nifty on July 9, 2026.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Dr Reddy's Laboratories reported a 68.7 per cent year-on-year decline in consolidated net profit to Rs 443.5 crore in Q1 FY27, primarily due to the end of its lenalidomide sales agreement, a Rs 240-crore provision for semaglutide API inventory quality issues, and elevated freight costs.
Indian stock markets witnessed a significant rally, with the Sensex climbing 964.58 points and the Nifty reaching 24,330, driven by strong buying in blue-chip stocks, particularly in the IT and banking sectors, amidst optimism over Q1 earnings and a shift towards large-cap investments.
Indian benchmark indices, Sensex and Nifty, experienced a significant downturn as escalating tensions in West Asia led to a sharp surge in crude oil prices, coupled with fresh foreign fund outflows and a weakening rupee.
Indian benchmark indices Sensex and Nifty continued their upward trend for a second consecutive day, with the Sensex gaining over 800 points, driven by strong performances from heavyweights like Reliance Industries, ICICI Bank, and HDFC Bank, alongside positive cues from easing crude oil prices and robust IT sector earnings.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
Indian benchmark indices Sensex and Nifty surged in early trade, with the Sensex jumping nearly 700 points, primarily driven by strong buying in IT stocks following TCS's positive June-quarter results and optimistic demand outlook. Track Sensex, Nifty on July 10, 2026.
Indian benchmark indices, Sensex and Nifty, experienced subdued trading and turned flat on Tuesday as investors engaged in profit-booking following a recent rally, compounded by weak Asian market trends and fresh foreign fund outflows.
Indian benchmark indices, Sensex and Nifty, staged a moderate rebound after a significant correction in the previous session, driven by foreign fund inflows and a largely positive trend in global markets, though geopolitical tensions between the US and Iran continued to foster caution.
Danish pharma major Novo Nordisk has launched 'Awiqli' in India, a once-weekly basal insulin injection for adults with diabetes, aiming to simplify treatment and reduce the burden of daily injections.
The Maharashtra Food and Drug Administration (FDA) conducted three separate operations in Pune and Kolhapur, seizing illegal medicines worth over Rs 24 lakh. Actions included seizing allopathic medicines from an unlicensed firm and prescription drugs with improper promotional packaging, with the FDA vowing strict action against violators.
Indian benchmark equity indices, Sensex and Nifty, extended their winning streak for a third consecutive day, driven by a rally in IT stocks and global cues suggesting a more accommodative monetary policy after softer-than-expected US jobs data.
'ISRO is planning to build a Bharatiya Antariksh Station by 2030. So, our goal is to create a vehicle that can supply modules to the Bharatiya Antariksh Station and bring the products back.'
The launch highlights the growing maturity of India's nuclear medicine ecosystem.
Indian benchmark indices, Sensex and Nifty, experienced a significant drop of over 1 per cent, driven by a bearish trend in global markets, weakness in HDFC Bank and IT firms, and fresh foreign fund outflows.
Indian stock markets, including the Sensex and Nifty, rebounded significantly, driven by a decline in crude oil prices and positive global cues stemming from hopes of diplomatic progress in US-Iran negotiations.
Hyderabad-based SETL, a precision engineering company, has acquired a 51% majority stake in GScale Energy Private Limited, an AI Datacenter Engineering infrastructure specialist. This strategic move involves an initial investment of Rs 190 crore, with a total commitment of Rs 500 crore, marking SETL's expansion into the rapidly growing AI Datacenter sector and leveraging its expertise from pharmaceutical and chemical industries.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
India's pharmaceutical exports have shown robust growth, reaching over USD 28 billion, despite global economic challenges. The sector is projected to reach USD 130 billion by 2030.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
